Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil ST; Zhang L; Martenyi F; Lowe SL; Jackson KA; Andreev BV; Avedisova AS; Bardenstein LM; Gurovich IY; Morozova MA; Mosolov SN; Neznanov NG; Reznik AM; Smulevich AB; Tochilov VA; Johnson BG; Monn JA; Schoepp DD; Nature Medicine, 2007, vol. 13, issue 9, p 1102, ISSN 10788956. ISBN 10788956.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef